Limitations, agreements, and source contact

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer · Source last updated 2017-04-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

limitations And Caveats

description

Early termination due to lack of activity of study drug.

point Of Contact

email

eric.chen@uhn.ca

organization

Princess Margaret Cancer Centre

phone

416-946-4501

phone Ext

2263

title

Dr.Eric Chen, Principal Investigator

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice